Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) shares traded up 4.6% during mid-day trading on Wednesday . The company traded as high as $22.20 and last traded at $20.68, with a volume of 1,235,240 shares trading hands. The stock had previously closed at $21.68.

A number of research analysts have issued reports on the stock. William Blair restated an “ourperform” rating on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. JMP Securities restated an “outperform” rating and set a $33.00 price target (up previously from $29.00) on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. Cowen and Company restated an “outperform” rating and set a $55.00 price target (up previously from $45.00) on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. BidaskClub upgraded shares of Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. Finally, Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $32.50.

The firm’s market cap is $471.44 million. The firm has a 50 day moving average price of $16.97 and a 200-day moving average price of $16.90.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.81) by $0.12. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The firm’s quarterly revenue was down 90.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.78) EPS. Equities research analysts forecast that Adamas Pharmaceuticals, Inc. will post ($3.79) EPS for the current fiscal year.

In other news, major shareholder Great Point Partners Llc sold 350,000 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $17.05, for a total transaction of $5,967,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 731,041 shares of company stock valued at $12,476,149 in the last 90 days. Insiders own 29.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in shares of Adamas Pharmaceuticals by 29.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 126,494 shares of the specialty pharmaceutical company’s stock worth $2,138,000 after buying an additional 28,994 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 3,358 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Adamas Pharmaceuticals by 2.4% in the first quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock worth $1,152,000 after buying an additional 1,563 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in shares of Adamas Pharmaceuticals by 153.3% in the first quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock worth $1,956,000 after buying an additional 67,654 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in shares of Adamas Pharmaceuticals during the first quarter worth approximately $1,750,000. 69.24% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/01/adamas-pharmaceuticals-inc-adms-trading-4-6-higher.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.